Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, you can still feel hungry on Mounjaro, particularly in the first few weeks or after a dose increase. Tirzepatide reduces appetite by activating GIP and GLP-1 receptors, but that effect builds gradually — hunger often persists at the lower starter doses before fading as the medicine reaches its clinical range. It does not mean the treatment is failing. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide works by activating two gut-hormone receptors, GIP and GLP-1, which together slow how quickly the stomach empties and send satiety signals to the brain. The NHS tirzepatide page explains this mechanism clearly. The catch is that these effects are dose-dependent: at 2.5 mg (the first four-week pen) the medicine is calibrating your system to tolerate it, not yet delivering its full appetite-reducing effect. Most people notice hunger softening meaningfully somewhere between 5 mg and 7.5 mg, though the timing varies.
If you're in the early weeks and still feeling hungry on Mounjaro, that is expected. It is one of the most common questions our prescribers field. Patience at this stage matters more than second-guessing the treatment.
There is also a distinction worth making between physical and habitual hunger. Tirzepatide quiets the physiological drive to eat, the kind triggered by ghrelin and blood-sugar fluctuations. It does not touch the urge to eat because you're bored, stressed, or because lunch always happens at noon regardless of appetite. For more on the mechanics behind this, our deep-dive into why hunger persists on Mounjaro covers the biology in more detail. Recognising which type of hunger you're experiencing is the first practical step.
When appetite suppression is partial, meal composition becomes the lever. Foods that digest slowly (protein, fibre, and fats) extend the feeling of fullness well beyond the plate. Rapidly digested carbohydrates (white bread, sugary drinks, ultra-processed snacks) clear the stomach quickly and can leave you feeling empty again within an hour, even on tirzepatide.
A practical starting point: anchor each meal around a palm-sized portion of protein (eggs, chicken, fish, legumes) then fill out with vegetables. Our Mounjaro food guide has worked examples. Hydration matters too; thirst and mild dehydration can register as hunger. Three to four glasses of water before midday often reduces the urge to graze.
Portion sizes naturally shrink on tirzepatide, so eating slowly enough for satiety signals to arrive (roughly 20 minutes) prevents the discomfort of overeating before you realise you're full, and keeps hunger from rebounding an hour later. If you want to make sure your protein intake is genuinely adequate as appetite falls, the protein calculator gives a quick reference.
A week-by-week note of when hunger strikes (time of day, what preceded it, how intense it was) gives your prescriber something concrete to work with. Hunger that is gradually reducing from week to week is a normal arc. Hunger that remains entirely unchanged after several weeks at a maintenance dose is a different conversation.
Under NICE's guidance on tirzepatide (TA1026), prescribers assess whether treatment is producing the expected response at intervals. If hunger and weight loss are both flat, a dose titration may be appropriate, but that is a clinical decision based on the whole picture, not something to adjust without prescriber input. On day two specifically, the medicine has barely begun, read more about what to expect on day two of Mounjaro if that's where you are.
Sleep is worth logging too. Poor sleep raises ghrelin (the hunger hormone) and blunts the satiety signals tirzepatide is trying to amplify. It is a common reason why hunger remains higher than expected and is easily missed.
Most hunger on Mounjaro in the early weeks resolves on its own as the dose increases. Some doesn't, and that's fine to name. Signs it is worth raising sooner rather than later include: hunger that is actively getting worse over successive weeks; feeling physically unable to stop eating despite being on a therapeutic dose; or noticeable mood changes around food.
Keep your medicine stored correctly too, tirzepatide needs refrigerating between 2°C and 8°C (the fridge door is fine for most household fridges), and a pen that has been left at room temperature for longer than the Patient Information Leaflet allows may not be working at full potency. That is a simple check worth making if nothing seems to be shifting. For a broader look at how Mounjaro works and what to realistically expect, the Mounjaro overview page is a good reference alongside the NICE appraisal of tirzepatide.
If you have concerns about your current treatment, or you're considering starting Mounjaro for the first time, speak to our prescribers, a named clinician reviews every consultation the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.